A/Prof FOLEFAC AMINKENG

Associate Professor (Genomics, Pharmacogenomics, Precision Health and Health Disparities), Medical College of Wisconsin

Research Expertise

Genomics
Pharmacogenomics and Precision Health

About

I am an Associate Professor in the Department of Neurology and the Head of the Laboratory for Genomics, Pharmacogenomics and Precision Health (PRECISE) at the Linda T. and John A Mellowes Center for Genomic Sciences and Precision Medicine at the Medical College of Wisconsin. Prior to that, I served as the Head of the Pharmacogenomics and Personalized Medicine Program at the Agency for Science Technology and Research (A\*STAR) Singapore, as Assistant Professor (joint appointment) in the Department of Medicine and the Department of Biomedical Informatics at the Yong Loo Lin School of Medicine at the National University of Singapore. I also served as a Faculty at the Centre for Precision Health (CPH) at the National University Health System (NUHS) in Singapore, the Pharmacogenomics Domain Expert for the Precision Medicine Coordination Office (PMCO) of the Ministry of Health, Singapore and on the NIH ClinGen, Pharmacogenomics Working Group (CLINGEN\_PGXWG) and the Executive board of the Pharmacogenomics Global Research Network (PGRN). I bring a wealth of experience, leadership, and scientific expertise in cutting- edge "Genomics, Pharmacogenomics and Precision Health Research and Innovations". My recent work focuses on Genomics, Pharmacogenomics and Precision Health research in Oncology and Neuroscience. As a Principal Investigator or Co-Investigator on several University, NIH, CHIR, and NMRC funded grants, I have successfully developed and implemented multiple projects focused on genomics, pharmacogenomics and precision health; collaborated with many global researchers; and have produced several high impact peer-reviewed publications in top scientific journals including Nature Genetics and JAMA ONCOLOGY. I have received several awards and recognition for my academic and scientific contributions, including the British Columbia Children’s Hospital Research Institute Outstanding Achievement award, Boehringer Ingelheim Award, Canadian Society of Pharmacology and Therapeutics Publication Award and the American Society of Human Genetics outstanding papers award. I am currently a member of several scientific consortia and working groups including the PGRN Psychiatry Special Interest Group, NIH CLINGEN\_PGXWG Nomenclature Survey Subgroup, NIH CLINGEN\_PGXWG Gene-Drug Validity Subgroup, Pharmacogene Variation Consortium and CPNDS Pharmacogenomics Clinical Practice Recommendations Group. I am also a member of several academic and professional organizations including the Pharmacogenomics Global Research Network, American Association of Pharmaceutical Scientists, British Pharmacological Society, European Society of Pharmacogenomics and Personalized Therapy, American Society of Human Genetics, Canadian Society for Pharmaceutical Sciences, Canadian Society of Pharmacology and Therapeutics, International Genetic Epidemiology Society, European Society of Human Genetics and African Society of Human Genetics. I have served on the Editorial Board of several journals including the Journal of Population Therapeutics and Clinical Pharmacology and as an editorial reviewer and ad hoc reviewer for several journals including Nature Genetics, Circulation – Journal of the American Heart Association, Mayo Clinic Proceedings, MDPI Pharmaceutic, Pharmacogenetics and Genomics, Canadian Journal of Cardiology, Clinical Genetics and Pharmacogenomics – Future Medicine.

Legacy Map

Full View

Publications

Pharmacogenomic strategies for the prevention of anthracycline-induced heart failure: A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer
Drug Metabolism and Pharmacokinetics
2017
Recommendations for genetic testing to reduce the incidence of anthracycline‐induced cardiotoxicity
British Journal of Clinical Pharmacology
2016
The emerging era of pharmacogenomics: current successes, future potential, and challenges
Clinical Genetics
2014
Unbiased Profiling of Isogenic Huntington Disease hPSC-Derived CNS and Peripheral Cells Reveals Strong Cell-Type Specificity of CAG Length Effects
Cell Reports
2019
The molecular epidemiology of Huntington disease is related to intermediate allele frequency and haplotype in the general population
American Journal of Medical Genetics Part B: Neuropsychiatric Genetics
2018
Pharmacogenomics of Vincristine‐Induced Peripheral Neuropathy Implicates Pharmacokinetic and Inherited Neuropathy Genes
Clinical Pharmacology & Therapeutics
2018
Association Between SLC16A5 Genetic Variation and Cisplatin-Induced Ototoxic Effects in Adult Patients With Testicular Cancer
JAMA Oncology
2017
Association and clinical utility of NAT2 in the prediction of isoniazid-induced liver injury in Singaporean patients
PLOS ONE
2017
Higher frequency of genetic variants conferring increased risk for ADRs for commonly used drugs treating cancer, AIDS and tuberculosis in persons of African descent
The Pharmacogenomics Journal
2013
Neutrophil-to-Lymphocyte Ratio Predicts Development of Immune-Related Adverse Events and Outcomes from Immune Checkpoint Blockade: A Case-Control Study
Cancers
2021
Association between the TCF7L2 rs12255372 (G/T) gene polymorphism and type 2 diabetes mellitus in a Cameroonian population: a pilot study
Clinical and Translational Medicine
2015
Contribution of the TCF7L2 rs7903146 (C/T) gene polymorphism to the susceptibility to type 2 diabetes mellitus in Cameroon
Journal of Diabetes & Metabolic Disorders
2015
Cytokine Release Syndrome in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Case Series of 25 Patients and Review of the Literature
Frontiers in Immunology
2022
Common variation near IRF6 is associated with IFN-β-induced liver injury in multiple sclerosis
Nature Genetics
2018
IFIH1 gene polymorphisms in type 1 diabetes: Genetic association analysis and genotype–phenotype correlation in the Belgian population
Human Immunology
2009
Risk factors for immune‐related adverse events from anti‐PD‐1 or anti‐PD‐L1 treatment in an Asian cohort of nonsmall cell lung cancer patients
International Journal of Cancer
2021
Association of KIR2DL2 polymorphism rs2756923 with type 1 diabetes and preliminary evidence for lack of inhibition through HLA‐C1 ligand binding
Tissue Antigens
2009
MICA is Associated with Type 1 Diabetes in the Belgian Population, Independent of HLA-DQ
Human Immunology
2006
Pharmacogenomic screening for anthracycline‐induced cardiotoxicity in childhood cancer
British Journal of Clinical Pharmacology
2017
Clinical and biological characteristics of diabetic patients under age 40 in Cameroon: Relation to autoantibody status and comparison with Belgian patients
Diabetes Research and Clinical Practice
2014
Neither an intronic CA repeat within the CD48 gene nor the HERV‐K18 polymorphisms are associated with type 1 diabetes
Tissue Antigens
2006
Pharmacogenomic diversity in Singaporean populations and Europeans
The Pharmacogenomics Journal
2014
HINT1 mutations define a novel disease entity – autosomal recessive axonal neuropathy with neuromyotonia
Clinical Genetics
2013
Association of IL-2RA/CD25 with type 1 diabetes in the Belgian population
Human Immunology
2010
Real‐world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non‐small cell lung cancer
Thoracic Cancer
2022
An Introductory Tutorial on Cardiovascular Pharmacogenetics for Healthcare Providers
Clinical Pharmacology & Therapeutics
2023
Genome-wide Scan Identifies Association Between an Interferon Regulatory Factor Variant and Interferon-beta Induced Liver Injury in Multiple Sclerosis Patients
Journal of Pharmacological and Toxicological Methods
2017
P2.05-05 Genomic Variants Associated with Response to Immune Checkpoint Inhibitors Amongst Asian Patients with Advanced NSCLC
Journal of Thoracic Oncology
2023
A Non-Coding Variant in LOC105371512 Confers Susceptibility to Bleomycin-Induced Lung Injury
Blood
2022
EP08.01-101 Factors Predictive of Primary Resistance to Immune Checkpoint Inhibitors in Asian Patients with Advanced NSCLC
Journal of Thoracic Oncology
2022
Pharmacogenomic prediction of immune-related adverse events from immune checkpoint inhibitors among Asian patients.
Journal of Clinical Oncology
2022
P75.10 Risk Factors for Immune-Related Adverse Events from Anti-PD-1/PD-L1 Treatment in an Asian Cohort of NSCLC Patients
Journal of Thoracic Oncology
2021
Pharmacogenomic Prediction of Bleomycin-Induced Pneumonitis in South East Asian Hodgkin Lymphoma Patients
Blood
2018
Pharmacogenomic Prediction of Cisplatin-Induced Nephrotoxicity in Patients Treated for Childhood Cancer
Journal of Pharmacological and Toxicological Methods
2017
Pharmacogenomic Prediction of Ribavirin-Induced Hemolytic Anemia in Patients Treated for Hepatitis C Infection
Journal of Pharmacological and Toxicological Methods
2017
Genetic Variation in SLC16A5 Confers Protection from Cisplatin-Induced Ototoxicity in Adult Testicular Cancer Patients
Journal of Pharmacological and Toxicological Methods
2017
Multifactorial Prediction of Anthracycline-Induced Cardiotoxicity in Childhood Cancer: 10 Years of Active Surveillance and Pharmacogenomics Studies at the Canadian Pharmacogenomics Network for Drug Safety
Journal of Pharmacological and Toxicological Methods
2017
OP13 Association entre le polymorphisme rs7903146(C/T) du gène TCF7L2 et l'obésité dans une population Camerounaise
Diabetes Research and Clinical Practice
2014
Factors Predictive of Primary Resistance to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer
Cancers
2023
An initial health economic evaluation of pharmacogenomic testing in patients treated for childhood cancer with anthracyclines
Pediatric Blood & Cancer
2017
DLL4 loss‐of‐function heterozygous mutations cause Adams–Oliver syndrome
Clinical Genetics
2015
PDGFRB mutation causes autosomal‐dominant Penttinen syndrome
Clinical Genetics
2015
A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer
Nature Genetics
2015
Association between the rs12255372 variant of the TCF7L2 gene and obesity in a Cameroonian population
BMC Research Notes
2015
EIF2AK4 genetic mutations cause a recessive form of rare and deadly lung disease, pulmonary veno‐occlusive disease
Clinical Genetics
2014
GFI1B mutation causes autosomal dominant gray platelet syndrome
Clinical Genetics
2014
Using pharmacogenetics in real time to guide therapy: the warfarin example
Clinical Genetics
2014
WDR45 mutations define a novel disease entity—Static Encephalopathy of Childhood with Neurodegeneration in Adulthood
Clinical Genetics
2013
KCNT1 mutations in ADNFLE and MMPSI: a new driver in the etiology and pathophysiology of early‐onset epileptic syndromes
Clinical Genetics
2013
Mutations in ATP1A3 cause alternating hemiplegia of childhood
Clinical Genetics
2013
TNFa microsatellite polymorphism modulates the risk of type 1 diabetes in the Belgian population, independent of HLA-DQ
Human Immunology
2007

Education

Vrije Universiteit Brussel

Doctor in Medical Sciences, Medical Biochemistry and Diabetes Research Centre / September, 2010

Brussel

Vrije Universiteit Brussel

Master Degree in Medical and Pharmaceutical Research, Medical Biochemsitry and Diabetes Research Centre / June, 2005

Brussel

University of Buea

Bachelor of Medical Laboratory Science, Medical Laboratory Science / August, 2001

Buea

Experience

Medical College of Wisconsin

Associate Professor / March, 2024Present

Principal Investigator / March, 2024Present

National University of Singapore

Faculty / August, 2021February, 2024

Assistant Professor / April, 2020February, 2024

Adjunct Assistant Professor / July, 2018December, 2019

Adjunct Assistant Professor / January, 2018December, 2019

National University Health System

Faculty / April, 2020February, 2024

Agency for Science, Technology and Research

Head - Pharmacogenomics and Personalized Medicine Program / February, 2017December, 2019

Assistant Principal Investigator / February, 2017December, 2019

University of British Columbia

Research Associate / April, 2016January, 2017

Postdoctoral Fellow / February, 2011March, 2016

University of Ottawa

Postdoctoral Fellow / December, 2010February, 2011

Join FOLEFAC AMINKENG on NotedSource!
Join Now

At NotedSource, we believe that professors, post-docs, scientists and other researchers have deep, untapped knowledge and expertise that can be leveraged to drive innovation within companies. NotedSource is committed to bridging the gap between academia and industry by providing a platform for collaboration with industry and networking with other researchers.

For industry, NotedSource identifies the right academic experts in 24 hours to help organizations build and grow. With a platform of thousands of knowledgeable PhDs, scientists, and industry experts, NotedSource makes connecting and collaborating easy.

For academic researchers such as professors, post-docs, and Ph.D.s, NotedSource provides tools to discover and connect to your colleagues with messaging and news feeds, in addition to the opportunity to be paid for your collaboration with vetted partners.

Expert Institutions
NotedSource has experts from Stanford University
Expert institutions using NotedSource include Oxfort University
Experts from McGill have used NotedSource to share their expertise
University of Chicago experts have used NotedSource
MIT researchers have used NotedSource
Proudly trusted by
Microsoft uses NotedSource for academic partnerships
Johnson & Johnson academic research projects on NotedSource
ProQuest (Clarivate) uses NotedSource as their industry academia platform
Slamom consulting engages academics for research collaboration on NotedSource
Omnicom and OMG find academics on notedsource
Unilever research project have used NotedSource to engage academic experts

Connect with researchers and scientists like A/Prof FOLEFAC AMINKENG on NotedSource to help your company with innovation, research, R&D, L&D, and more.